Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
Working Life
Novartis' new 'disruptive' HQ
Novartis is planning a brand new HQ aiming to bring together all its group member in a state-of-the-art, collaborative environment that may be just a bit disruptive.
Approvals Action
More competition for Diovan
Alphapharm has registered two new brands of valsartan, joining the line-up of competitors for Novartis Diovan and its sister brands.
Special Report
New label rules could curb competition
Pharmaceutical brand owners have been offered some relief by the TGA's new draft Therapeutic Goods Order but a labelling headache is still on the horizon write Frances Drummond and Emma Bekens.
Special Report
PBAC November agenda
Our presentation of the PBAC November agenda has been divided into major and minor submissions and sorted by indication.
Pipeline Monitor
BMS next up in hep C
BMS' wins key hep C approval in Europe; Sanofi's Genzyme unit given go ahead for oral Gaucher therapy; GSK adds to respiratory portfolio.